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Background: Neuroblastoma is the most common extra-cranial solid tumor in
children. Intensive therapy including autologous stem-cell transplantation (HSCT) has
improved the poor prognosis of high-risk neuroblastoma (HR-NBL) but may impair
gonadal function.
Objectives: To investigate the gonadal function and fertility in long-term survivors of
childhood HR-NBL.
Design: A cohort including all Finnish (n = 20; 11 females) long-term (>10 years)
survivors of HR-NBL and an age- and sex-matched control group (n= 20) was examined
at a median age of 22 (16–30) years. Oncologic treatments, pubertal timing, hormonal
therapies and the number of off-spring were recorded, and pituitary and gonadal
hormones were measured.
Results: Altogether 16/20 of the long-term survivors of HR-NBL entered puberty
spontaneously; puberty was hormonally induced in four survivors (three females). Among
the 8/11 female survivors with spontaneous puberty, seven had spontaneous menarche,
but 5/8 developed ovarian failure soon after puberty. Nine females currently needed
estrogen substitution. AMH, a marker of ovarian reserve, was lower in the female
survivors than controls (median 0.02 vs. 1.7 µg/l, p < 0.001). As a group, male survivors
had smaller testicular size (8.5 vs. 39ml, p < 0.001) and lower inhibin B (<10 vs. 170
ng/l, p < 0.001) compared with control males, with altogether 6/9 survivor males fulfilling
the criteria of gonadal failure (absent puberty, small testicle size or increased FSH with
need of testosterone substitution). Gonadal failure was more common in female andmale
survivors treated with total-body irradiation. Three survivors (one male) had offspring, all
treated without total-body irradiation and moderate dose of alkylating chemotherapy.
Growth velocity was compromised in all survivors after HR-NBL diagnosis, with
absent pubertal growth spurt in 7/17 survivors with complete growth data.
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Conclusion: Gonadal failure is common in long-term survivors of HR-NBL treated with
HSCT. Fertility may be preserved in some survivors treated without total-body irradiation.
Keywords: high-risk neuroblastoma, irradiation, chemotherapy, late effect of cancer treatment, gonadal function,
gonadal failure, fertility, puberty
INTRODUCTION
Neuroblastoma (NBL) is the most common extra cranial
malignant solid tumor in childhood. Approximately one-half
of the NBL patients present with high-risk features (1, 2).
The prognosis of high-risk neuroblastoma (HR-NBL) has long
remained poor but improved with intensive multimodal therapy
(1) including multi-drug induction chemotherapy, surgical
resection of primary tumor with/without local irradiation,
myeloablative therapy together with autologous hematopoietic
stem-cell transplantation (HSCT), and 13-cis-retinoic acid
consolidation (3–6).
Neuroblastoma is typically a disease of small children.
Aggressive treatment at young age predisposes the HR-NBL
patients to a high risk of adverse effects. The gonadotoxicity
of alkylating chemotherapy is well-described, and total-body
irradiation (TBI), previously used as conditioning for HSCT
in some HR-NBL patients, may lead to gonadal failure (7, 8).
However, surprisingly little is known about long-term gonadal
function after childhood HSCT.
The poor prognosis has limited the study of late effects of
HR-NBL. Thus far, no live birth after HR-NBL treatment has
been reported. A recent retrospective study onHR-NBL survivors
reported premature ovarian insufficiency (POI) in 75% (9/12) of
the pubertal/post-pubertal girls (9). Other studies also list ovarian
failure as a common late adverse effect in female survivors of
HR-NBL (10, 11). Less is known about gonadal function in male
HR-NBL survivors.
A short adult height is an acknowledged sequela of childhood
HR-NBL (9, 12–15), typically associated with TBI. Most probably
multiple mechanisms underlie the growth failure, among them
also retinoic acid treatment by leading to premature closure of
growth plates and thereby premature cessation of growth (16).
To elucidate the influence of childhood HSCT and HR-NBL
on gonadal outcome, we investigated the pubertal development
and indicators of gonadal function in long-term survivors of HR-
NBL. We also systemically analyzed the childhood and pubertal
growth in our cohort to better understand the growth deficit
in HR-NBL.
MATERIALS AND METHODS
Study Population
A national cohort of long-term (>10 years) survivors of HR-
NBL treated at the University Hospitals in Finland between 1980
and 2000 were invited to participate in this follow-up study. Of
the identified 23 long-term survivors, 20 (87%) consented and
completed the current follow-up visit; laboratory examinations
were obtained for 19/20 subjects. The clinical and treatment
characteristics of the enrolled cohort (17), and the outcome of the
patients treated at Helsinki University Hospital (4, 18) have been
previously published. The characteristics of the cohort are shown
inTable 1. The control group comprised 20 healthy, age- and sex-
matched paired controls, as previously described (17). Informed
written consent was received from all the study subjects, and
in case of pediatric participants, also from the guardians. The
institutional review board approved the study, and it was carried
out in accordance with the Declaration of Helsinki.
Clinical and Laboratory Evaluations
All subjects (HR-NBL n = 20; controls n = 20) had physical
examination by the same physician (AS). Blood samples (HR-
NBL n= 19; controls n= 20) for pituitary and gonadal hormone
analyses were drawn after an over-night fast between 8.30 and
9.15 a.m. on the examination day. Data on pubertal development,
pubertal induction and sex hormone substitution were collected
from hospital records, and confirmed with a questionnaire and
interview. The oncologic treatments are described in Figure 1.
The cumulative dose of alkylating chemotherapy was calculated
using cyclophosphamide equivalent dose (CED) as described
(19). The cumulative doxorubicin, the only used anthracycline,
and cisplatin doses were calculated. Testis size exceeding 15ml
was regarded normal (20). Gonadal failure was defined as:
(A) absent pubertal development, (B) history of increased
gonadotropins [FSH exceeding 10.4 IU/l for males (21)] after
spontaneous puberty needing hormonal replacement therapy
(HRT), (C) small post-pubertal testis size (<15ml) as a predictive
sign of non-functional spermatogenesis (20). Sufficient growth
data with at least biannual measurement of height until 15 years
of age were obtained for 17/20 HR-NBL subjects. All height
measurements were transformed into standard deviation scores
(SDS) according to Finnish growth standards (22). For each
subject, an individual growth curve was drawn. We also analyzed
height SDS at the diagnosis of HR-NBL, at the end of treatment,
at pre-pubertal age (∼5 years after completing the treatment but
before pubertal growth), at pubertal peak height velocity, and at
final height. The magnitude of pubertal growth spurt (greatest
growth velocity) was evaluated by inspecting each individual
growth curve.
Statistical Analyses
Data analyses were performed using IBMSPSS statistical software
for Windows, Version 25.0 (IBM Corp., Armank, NY, U.S.). Due
to the small sample size, the non-parametric Mann-Whitney U
test was used for all group comparisons, and data are presented as
median ± interquartile range or range, as appropriate. Fischer’s
exact test was used to compare binary variables between the study
groups and subgroups. All statistical analyses were 2-sided, and
p-values ≤0.05 were considered significant.
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TABLE 1 | Clinical and treatment characteristics, and gonadal hormone
concentrations [median [interquartile range] or (range)] in the survivors of high-risk
neuroblastoma (HR-NBL; n = 20), and their healthy controls (n = 20).
HR-NBL (n = 20) Control (n = 20) p
Gender (female/male) 11/9 11/9 –
Age at HR-NBL
diagnosis (years)
(range)
1.6 (0.2–3.6)
Age at HSCT (years)
(range)
2.3 (1.0–4.1)
TBI (yes/no) 10/10
Local RT 14/20
CED (mg/m2) (range) 9,900 (5,600–62,400) – –
DIE (mg/m2) (range) 120 (0–210) – –
Cisplatin cumulative
(mg/m2) (range)
320 (180–820) – –
Median follow-up
time (years) (range)
19 (13–27)
Age (years) (range) 21.7 (15.9–30.1) 22.1 (15.6–30.0) 0.92
BMI (kg/m2) 20.6 [19.0; 23.6] 22.3 [21.4; 26.3] 0.055
Height SDS −3.0 [−3.4; −1.0] 0.3 [−0.7; 1.2] <0.001
Sitting height (range) 0.519 (0.44–0.55) 0.532 (0.51–0.56) p < 0.001
HR-NBL male
(n = 9)
Male control
(n = 9)
Testis volume (ml) 8.5 [5.8–17] 39 [29–49] p < 0.001
Inhibin B (ng/l) <10 [<10–26] n = 8 166 [138–173] p < 0.001
Testosterone (nmol/l)* 12.3 [8.5; 16.3] *n = 6 18.9 [14.8; 26.6] p = 0.05
AMH (µg/l) 2.1 [0.30; 3.30] n = 8 3.4 [2.4; 11.6] p = 0.07
FSH (IU/l)* 26.3 [14.2; 36.1] *n = 6 3.70 [2.2; 7.3] p < 0.001
LH (IU/l)* 10.0 [8.3; 19.3] *n = 6 4.1 [3.1; 6.8] p = 0.005
HR-NBL female
(n = 11)
Female control
(n = 11)
AMH (µg/l) (range) <0.2
(<0.02–0.29)
1.7
(0.5–6.6)
p < 0.001
Estradiol (µmol/l)
(range)*
0.1
n = 1
0.28
(0.11–0.65)
NA
FSH (IU/l) (range)* 7.5
n = 1
4.9
(1.7–8.4) n = 4
NA
LH (IU/l) (range)* 4.1
n = 1
4.3
(0.7–35.6) n = 4
NA
Median (range) or median [interquartile range].
HR-NBL, high-risk neuroblastoma; HSCT, hematopoietic stem cell transplantation; TBI,
total-body irradiation; CED, cyclofosfamide equivalent dose; DIE, doxorubicin equivalent
dose (anthracycline chemotherapy); BMI, body mass index; testo, testosterone; sitting
height, sitting height to total height ratio; AMH, anti-Müllerian hormone.
*Ten of the 11 female survivors and three male survivors were on hormone
(estrogen/testosterone) substitution, and 7/11 control females were on estrogen
containing e-pills, and their LH, FSH, E2/testosterone values were excluded from
the analysis.
Italic font refers to significant p values.
RESULTS
Gonadal Function
The treatment characteristics, pubertal development and
indicators of gonadal function are described in Tables 2, 3.
Puberty was hormonally induced due to delayed/absent pubertal
development in four survivors (one male; three with TBI). None
of the survivors presented with true precocious puberty. Because
of early puberty (not fulfilling the criteria of precocious puberty)
and/or moderate bone age advancement, four male survivors
were treated with GnRH-analog (n = 2) or letrozole (n = 2)
in an attempt to delay epiphyseal closure and maximize the
final height (Table 2). The concentrations of gonadotropins and
gonadal hormones are shown in Table 1.
Male Gonadal Function
Altogether 6 male survivors were defined as having gonadal
failure (Table 2). In four of these, gonadal failure manifested
at adolescence as small atrophic testes together with high FSH
and low testosterone levels and in one as absent pubertal
development. At the current examination, the male survivor
group had smaller testicular volume, lower inhibin B and higher
FSH (those without testosterone substitution) concentrations
compared with male control group, and a trend toward lower
AMH concentrations (Table 1). Three male survivors were
on testosterone substitution; all the remaining male survivors
presented with abnormally high FSH concentrations [>10.4 IU/l
(19)] (Table 2).
Altogether 3 male survivors had testis volume >15ml, none
of them treated with TBI. Their median CED (10,800 vs. 9,300
mg/m2, p = 0.90), cumulative cisplatin (360 vs. 280 mg/m2,
p = 0.56) or doxorubicin doses (0 vs. 120 mg/m2, p = 0.18) did
not differ from the other survivor males. These survivor males
had higher median inhibin B and AMH compared with survivor
males with small testicle size (26 vs. <10 ng/ml, p = 0.003 and
3.4 vs. 1.1µg/ml, p = 0.024, respectively). Inhibin B was below
the normal reference range in all survivor males (Table 1), with
no significant difference between TBI-treated and other survivor
males (median <10 vs. <10 ng/ml, p = 0.79). There was a trend
toward lower AMH levels in the TBI-treated compared with
other survivor males (0.02 vs. 2.8 mg/l, p= 0.14).
The only male survivor with off-spring had normal testis
volume but high FSH and low inhibin B level. His HR-NBL
treatment had included induction chemotherapy with cisplatin
and etoposide, andmelphalan as the high-dose therapy, summing
up with CED of 5,600 mg/m2. His sperm analysis showed oligo-
asthenozoo-spermia with total sperm count 0.80 E6/ml (reference
range of the laboratory >20 E6/ml). Sperm analysis was not
performed in other male survivors.
Female Gonadal Function
Altogether eight (73%) of the 11 female survivors were
defined as having gonadal failure (TBI treated 6/6 vs. non-TBI
treated 2/5) (Table 3). Among them, both two non-TBI treated
females had received tandem HSCT, and the other also RT at
pelvic/abdominal area (Patients 7–8, Table 3). Altogether 9/11
female survivors were currently on estrogen substitution that had
been started at pubertal induction (n = 3), during/after puberty
when gonadotropin levels continuously increased exceeding the
reference range (n = 5) or when secondary oligo-amenorrhea
manifested (n = 1). All the survivor females with previously
diagnosed gonadal failure had presented with high LH and/or
FSH prior to estrogen substitution. Despite estrogen substitution,
three female survivors had a FSH level exceeding the reference
range at current examination. AMH was <0.02 µg/L, the lower
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FIGURE 1 | Oncologic treatment in the 20 long-term survivors of high-risk neuroblastoma. COD, cyclophosphamide + vincristine + DTIC; AAP, ciplatin +
doxorubicin; HSCT, hematologic stem cell transplantation; TBI, total-body irradiation.
limit of the analysis, in all survivor females except one treated
without TBI (Tables 1, 3).
Eight survivor girls entered puberty spontaneously, and
7/8 of them also had spontaneous normally-timed menarche
(mean 12.7 years) but 5/8 of them manifested ovarian failure
with increasing gonadotropin levels post-pubertally (Table 3).
Altogether three female survivors manifested signs of preserved
ovarian function and two of them had been pregnant (patients
9–11, Table 3). They had been treated with single HSCT, without
TBI and melphalan as the high-dose treatment, with CED:s
≤9,600 mg/m2. Two of them were on estrogen-containing
contraceptive pills, one for birth control and one because of
oligomenorrhea. They both had therefore low FSH and LH at
current examination. The only female survivor without current
estrogen treatment had normal FSH and LH (Table 1).
Pregnancies and Off-Spring
Three HR-NBL survivors (one male) had carried/fathered
altogether nine pregnancies, all treated without TBI and with
CED of 5,600 mg/m2. One pregnancy was electively terminated;
the live-born children had the following gestational ages
(premature/full-term, FT) and birth weights: premature week
23/610 g; FT/3.620 kg; FT/3.640 kg; FT/3.395 kg; FT/2.850 kg;
FT/3.526 kg; FT/3.370 kg; FT/3.720 kg. No miscarriages were
reported by the survivor females. The preterm baby was deceased
during the neonatal period. All full-term born children were
healthy with no birth anomalities.
Growth
Figure 2 shows height SDS at different time points in relation to
HR-NBL treatment and puberty (n = 17), separately for those
with and without growth hormone (GH) therapy. The final
height SDS (median −3.0 SDS, Table 1) was lower than height
SDS at HR-NBL diagnosis in each subject. The pubertal growth
spurt was absent or blunted in 7/17 survivors (three females, four
males; 6/7 with TBI), uninterpretable in 2 females and normal
in 8 survivors. Among those with pubertal growth spurt, it was
precocious in three males and late in one female. At puberty,
bone age was delayed in all survivor girls, while moderately (1–
2 years) advanced bone maturation had been recorded in four
males (2 TBI-treated). The median sitting height was lower in the
survivors than the controls (Table 1). Typical individual growth
curves of HR-NBL survivors with growth deficit are presented in
Figure 3.
Altogether ten (50%; six female) survivors had received GH
therapy, nine (90%) of them treated with TBI. Only three of them
(all females) had laboratory-proven GH deficiency while others
were treated based on the treating endocrinologist’s judgment of
the growth deficit. None of the subjects continued on GH after
completion of growth. Overall the response to GHwas poor. Two
of the GH-treated subjects showed improved growth velocity
during GH therapy. Despite the treatment, final height remained
extremely low (between −4.3 and −7.5 SDS) in all the male
survivors with GH therapy. They all were TBI treated, without
laboratory-proven GH deficiency and 2/4 of them also had severe
kidney insufficiency. Altogether 10 survivors (eight with TBI) had
hypothyroidism that was timely substituted (Tables 2, 3).
DISCUSSION
This national cohort study explores the gonadal function and
fertility after HR-NBL in detail, and it shows that most male (6/9)
and female survivors (8/11) of HR-NBL present with gonadal
failure at young adulthood.
All male survivors treated with TBI presented with gonadal
failure as defined by increased FSH together with low testosterone
concentration and small testis volume (<15ml). All the non-TBI
treated survivor males had high FSH and low inhibin B levels,
although the strict definition of gonadal failure was not fulfilled
in all of them. There were three non-TBI treated survivors
with testicular size exceeding 15ml, which in a previous study
predicted spermatogenic recovery after childhood allogeneic
HSCT (20). In our cohort, cumulative doses of alkylating agents,
cisplatin or anthracyclines did not correlate with testis size,
probably because treatment included also TBI in half of the
patients, which confounds the correlations. Some previously
reported HR-NBL survivor cohorts, treated with comparable
intensive protocols, also report pubertal/gonadal failure in many
survivors (9, 12, 23) but they did not investigate gonadal function
in more detail, and follow-up usually did not extend to adult age.
Altogether 67% of long-term survivor males presented with low
inhibin B as a marker of gonadal failure in a large childhood
cancer cohort (24). In that study, NBL survivors were among the
most affected subgroups, our findings being in line with this.
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TABLE 2 | Pubertal development, need of hormone substitution and cumulative alkylating chemotherapy in male survivors (n = 9) of childhood high-risk neuroblastoma.
Patient TBI Local
RTα
CED
(mg/m2)
Follow-up
time
(years:s)
Puberty initiation
(spontaneous/
induced)
Pubertal
induction
therapy/age
Testis size
(ml)
Inhibin B
(ng/l)
Gonadal failure with need
of HRT or small testis
size
Testosterone
substitution
(from age)
Hypothyroidism Other
TBI TREATED
1 + + 7,400 19.7 Spontaneous
normally timed
No 6 11 YES; increased
gonadotropins and low
testosterone post-pubertally
before HRT
Yes, 15 years -> + Bone age
advancement during
puberty; Letrozoleβ
2 + – 8,650 21 Spontaneous early
puberty£
No 9 UN/A YES; increased
gonadotropins, decreasing
testosterone before HRT
Yes, 20 years -> + GnRH-analog for
delaying puberty
3 + – 9,900 23 Hormonally
induced
Yes/13
years
1 <10 YES, increased FSH and
low testosterone before
HRT
Yes, 13 years -> + Letrozoleβ
4 + – 11,400 24.2 Spontaneous
early£
No 9 <10 YES, increased
gonadotropins, low
testosterone and small
testis size
Not currently
(previously from 18
years ->)
+ GnRH-analog for
delaying puberty
Summary TBI 1/4 Mean Mean Spontaneous
puberty 3/4
Induction 1/4 Mean 6ml All below the
reference
range
4/4 4/4 (currently 3/4) 4/4
NO TBI
5 – + 10,840 14.2 Spontaneous
normally timed
No 19 <10 NO; high FSH but normal
testosterone and testis size
No – BA advancement
during puberty
6 – – 46,830 13.9 Spontaneous early
(no hormonal
treatment)
No 16 26 NO; high FSH but normal
testosterone and testis size
No – BA advancement
during puberty
7 – + 5,600 26 Spontaneous
puberty
No 6 <10 YES; high FSH, low
testosterone and small
testis size
No – –
8 – + 45,000 16.8 Spontaneous
normal
No 8 <10 YES; high current FSH,
normal testosterone but
small testis size
No – –
9 – – 5,600 27.4 Spontaneous
normally-timed
No 20 26 NO; high current FSH and
low testosterone but normal
testis size
No – Has offspring
Summary no TBI 3/5 Mean Mean All with
spontaneous
puberty
Induction 0/5 Mean 14ml All below the
reference
range
2/5 0/4 0/4
TBI, total-body irradiation; RT, radiotherapy; CED, cyclophosphamide equivalent dose (=cumulative dose of alkylating chemotherapy); testo, testosterone; HRT, hormone replacement therapy.
αLocal RT retroperitoneal.
$ In two males, early spontaneous puberty was treated with GnRH-analog in order to suppress gonadotropins and optimize the growth potential.
β In two males, letrozole was used in order to optimize the growth potential in height by suppressing bone age advancement.
U In one male subject, laboratory test were not taken at current evaluation, although he had consented to participate in the study.
Normal testis volume >15ml marked with italic.
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TABLE 3 | Pubertal development, need of hormone substitution and cumulative alkylating chemotherapy in female survivors (n = 11) of childhood high-risk neuroblastoma.
Patient TBI Local
RTα
CED
(mg/m2)
Puberty
(spontaneous or
induced)/age
Spontaneous
menarche/
age
Ovarian failure
with high
gonadotropins
and need of HRT
Estrogen
substitution (±),
since age
Current HRT AMH (µg/l) Hypothyroidism Other
TBI TREATMENT
1 + + 8,600 Spontaneous
puberty
YES, at 13
years
YES; develops
after spontaneous
menarche
YES from 13 years YES ≤0.02 –
2 + (+) 11,400 Spontaneous
puberty
NO YES; develops
after puberty
YES, from 14
years
YES ≤0.02 +
3 + – 7,500 Spontaneous
puberty
Yes, at 12.5
years
YES; develops
after spontaneous
menarche
YES, from 14
years
YES ≤0.02 –
4 + + 9,900 Hormonally
induced at 13
years
No YES YES, from 13
years
YES ≤0.02 +
5 + + 9,900 Spontaneous
puberty
YES, at 12
years
YES; develops
after spontaneous
menarche
YES, from 16
years
YES ≤0.02 –
6 + + 40,650β Hormonally
induced at 11.5
years
NO YES YES, from 11.5
years
YES ≤0.02 +
TBI summary 5/6 14,700 Spontaneous 4/6 Menarche 3/6 6/6 6/6 6/6 All with ≤0.02 3/6
NO TBI TREATMENT
7 – (+) 39,900β Hormonally
induced at 13
years
No YES YES, from 13
years
YES ≤0.02 +
8 – + 62,400β Spontaneous
puberty
YES, at 13.5
years
YES; develops
after spontaneous
menarche
YES, from 14
years onwards
YES ≤0.02 –
9 – (+) 9,600 Spontaneous
puberty
YES at 13
years
NO NO (but E-pills for
pregnancy control)
NO ≤0.02 –
10 – + 5,600 Spontaneous
puberty
YES, at 13.5
years
NO NO NO 0.40 + History of
pregnancy
11 – + 5,600 Spontaneous
puberty
YES, at 12
years
Partial; develops
after spontaneous
pregnancies
YES; E-pills
(oligomenorrhea)
YES ≤0.02 – History of
pregnancy
No TBI summary 5/5 24,600 1/6 4/5 2/5 3/5 3/5 ≤0.02 in 4/5 2/5
αLocal RT at abdominal or lumbosacral area +, other areas (+).
βTandem HSCT, first with melphalan and the other with thiotepa ± TBI.
CED, cyclophosphamide equivalent dose (=cumulative dose of alkylating chemotherapy); TBI, total-body irradiation; HRT, hormone replacement therapy; AMH, anti-Müllerian hormone.
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FIGURE 2 | Height SDS in relation to oncologic treatment and puberty in
long-term survivors of HR-NBL (n = 17). Height SDS measured at/before
diagnosis (dg; median age at measurement 1.6 years, range 0.0–4.3), at the
end of HR-NBL treatment (end of th; median 2.4 years, range 1.4–4.4), at
pre-pubertal age (pre-puberty; median 7.8 years, range 6.5–8.8), at pubertal
peak height velocity (puberty; median 13.1 years, range 11.8–14.8) and at final
height. Growth patterns are shown separately for those with GH treatment (A)
and for those without GH treatment (B). Among the GH treated, GH treatment
was started at mean age of 7.6 years (between 4 and 11). Those treated with
TBI are marked with solid line and those without TBI with dotted line.
Altogether 10 had hypothyroidism (7 with GH treatment; 3 without GH
treatment) substituted with thyroxine.
While both inhibin B and FSH correlate with sperm cell
count, they are only surrogatemarkers of male germ-cell function
and have not succeeded in predicting azoospermia in some
childhood cancer survivor cohorts (25). One study on childhood
cancer survivors suggested a FSH level exceeding 10.4 IU/l to be
predictive of gonadal failure (21), but another study indicated
that inhibin B is a better marker of spermatogenesis than FSH or
other hormones (26). Although inhibin B has not been validated
as a marker of male gonadal failure after childhood cancer
treatment, extremely low levels of inhibin B in our survivor males
probably indicate some stage of gonadal damage and defected
Sertoli cell function.
The gonadotoxicity of TBI and alkylating chemotherapy is
well-known (27). In long-term survivors of allogenic HSCT,
TBI was associated with smaller testicular size and lower sperm
count (20). In our cohort, the only male survivor with off-
spring—assumingly with best preserved germ-cell function—also
presented with high FSH, low inhibin B level and low sperm
count, albeit normal testicular size. His treatment did not include
TBI and CED of 5,600 mg/m2 was among the lowest in our
cohort, with melphalan as pretreatment for HSCT. Otherwise,
clear associations between treatment modalities and fertility
markers could not be demonstrated.
In general, Sertoli cell and germ-cell function are more
vulnerable to cancer treatments than Leydig cell function (7, 27).
Also many of our non-TBI treated survivor males had normal
testosterone levels, while all presented with extremely low inhibin
B and high FSH levels. In adult males, AMH may serve as a
biomarker of subacute testicular toxicity with higher values after
cisplatin and alkylating chemotherapies suggesting testicular
damage or “dematuration” of Sertoli cells (28). On the contrary,
our male survivors with small testicle size and several years since
treatment had low serum AMH levels with raised FSH. This has
been demonstrated as a typical pattern for Sertoli cell damage
following childhood HSCT and predicts azoospermia (29).
POI is well-known sequela of childhood cancer (30). Exposure
to irradiation and alkylating agents results in DNA damage
that induces primordial follicle oocyte death, and POI (31, 32).
Recent studies have provided evidence that that oocytes at all
stages of development have the capacity to repair damaged DNA
(33). In turn, defects in DNA repair capacity caused by cancer
therapy may contribute to secondary POI in some patients due to
accelerated loss of the damaged germ cells (33). Ovarian failure,
as defined by either absent pubertal development or abnormally
high circulating gonadotropin concentrations needing estrogen
substitution, was common in our female survivors. The risk of
ovarian failure was determined by TBI: all TBI-treated female
survivors but only two survivors without TBI (both with tandem
HSCT:s) were affected. In most cases, ovarian failure manifested
after spontaneous puberty. It is notable that even those with
spontaneous menarche ended up with premature menopause
and HRT already few years after menarche, this observation
being consistent with severely reduced ovarian reserve. AMH, a
production of granulosa cells of the growing follicles (34), reflects
the size of primordial follicle pool (35), and is regarded a measure
of ovarian reserve (34, 36). AMHwas extremely low in all but one
of our female survivors, indicating reduced ovarian follicle pool.
Three female survivors, all treated without TBI, had partially
preserved ovarian function as indicated by pregnancies or normal
gonadotropins and regular menstruation, after spontaneous
puberty-menarche. Nevertheless, two of them also presented
with low AMH at young adulthood, indicating increased risk
of developing POI. Importantly, these women probably have
preserved fertility during a narrow window, which should be
considered early during their follow-up in order to provide
timely information on fertility possibilities. In previous studies,
the risk of POF has been highest when alkylating chemotherapy
has been combined with pelvic or abdominal radiotherapy (30,
37). In our cohort, those with best preserved ovarian function
were treated with melphalan as the high-dose treatment and
with CED of <10,000 mg/m2. This finding is in line with a
previous study showing better preserved ovarian function with
melphalan-based conditioning compared to busulfan-containing
conditioning regimens for HSCT (38).
As reported in our cohort (15) and others (9–13), growth
failure is common in HR-NBL survivors. In the current study, we
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FIGURE 3 | Representative individual growth curves in height in long-term survivors of high-risk neuroblastoma (HR-NBL), shown in height SD scores according to
Finnish growth curves, with age in years at X axis and height SDS at Y axis. (A–D) Male survivors of high-risk neuroblastoma: (A,B) TBI treated. Growth failure begins
after HR-NBL diagnosis and becomes more pronounced with lacking pubertal growth spurt. (C) No TBI. Normal growth velocity after HR-NBL treatment, but mildly
compromised adult height due to early pubertal growth spurt. (D) No TBI. Growth failure after HR-NBL treatment, and early pubertal growth spurt leading to further
compromised adult height. (E–H) Female survivors of HR-NBL. (E) TBI treated. Slightly compromised growth velocity after HR-NBL treatment in early childhood, but
after that (with GH) normal growth and normal pubertal growth. (F) No TBI. Pronounced growth failure begins after HR-NBL treatment; blunted pubertal growth spurt.
(G–H) Both TBI treated. Growth failure begins after HR-NBL treatment and is further augmented with blunted pubertal growth. Long arrow, GH treatment begins;
short arrow, thyroxine substitution for hypothyroidism begins.
found that pubertal growth spurt was absent or blunted in one
third of the survivors. The significance of pubertal growth on the
final height was, nevertheless, rather small, since growth velocity
was typically decreased already during the first years following
HR-NBL treatment. It is noteworthy that many survivors had
other possible causes of growth failure: hypothyroidism, GH
deficiency or severe kidney dysfunction. Further mechanisms
underlying growth deficit may include direct spinal growth plate
damage by radiation, as suggested by the more pronounced
growth failure in the TBI treated (15) and directly indicated
by the lower sitting height percentage in our survivors in the
current study. Still another possible cause of growth deficit
is premature closure of growth plates due to retinoic acid
treatment, as suggested previously (16). Indeed, some of our
male survivors had advanced bone maturation in the context of
normally-timed or slightly early puberty and short stature for
age, which could relate to retinoic acid treatment. Three male
survivors also manifested early puberty and pubertal growth
spurt that seemed to compromise their final height. Further,
nutritional deprivation during and after the HR-NBL treatment
may contribute, explaining the slow growth rate during the
childhood growth (39), as discussed before (15). As for the
significance of GH deficiency, a true deficit of GH could seldom
be demonstrated biochemically in our subjects. And in turn, GH
treatment was unable to significantly improve the final height in
most cases.
Although we describe a national HR-NBL survivor cohort,
the size of each subgroup is too small for detailed analyses
on the effect of each treatment modality on gonadal function.
Unfortunately, sperm analysis was not performed in this study.
Although inhibin B is regarded a marker of Sertoli cell function
and related to germ-cell function, it does not directly measure
germ-cell viability. Transvaginal ovarian ultrasound was not
performed, and therefore only indirect measures of ovarian
follicle pool could be used. TBI is no longer used in HR-NBL
patients, but half of the cohort patients were treated without
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TBI, similar to HR-NBL patients today. Moreover, knowledge
of the combined effects of TBI and chemotherapy is relevant
for the long-term survivor women in whom fertility options are
currently evaluated. The strength of the study is the long follow-
up from diagnosis until young adulthood, detailed description of
pubertal development and careful clinical examination.
In conclusion, we demonstrate that gonadal damage is
common in long-term survivors of HR-NBL treated with HSCT.
Importantly, those treated without TBI were also affected.
Fertility may remain preserved in some survivors, especially
in those treated with chemotherapy (melphalan)-based high-
dose regimens and with moderate cumulative doses of alkylating
agents. Nevertheless, gonadal vulnerability differs between
patients with same treatment warranting careful clinical follow-
up with appropriate regular laboratory evaluations. Importantly,
even in female survivors with spontaneous menarche, fertile
period may be short because of reduced primordial follicle
reserve. Therefore, only a narrow window maybe offered for
fertility strategies, which warrants early information about
pregnancy options. Fertility counseling and option for fertility
preservation should be routinely given to all HR-NBL patients at
diagnosis and repeated at pubertal age in all survivors.
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